Evidence‑Based Quetiapine Dosing for Special Populations

Dementia‑Related Agitation

Cancer‑Related Delirium

Safety Considerations

Orthostatic Hypotension

Excessive Sedation

Quetiapine Dosing Considerations in Special Populations and Clinical Contexts

Elderly Patients (≥ 65 years)

• Older adults have an increased risk of orthostatic hypotension, falls, and cognitive adverse effects when treated with quetiapine; therefore, clinicians should use lower initial doses and titrate slowly. 4

Dementia‑Related Agitation (Alzheimer’s disease and other dementias)

• For behavioral disturbances in dementia, start quetiapine at 12.5 mg twice daily and do not exceed 200 mg twice daily; the drug is more sedating than other atypical antipsychotics, so orthostatic hypotension should be monitored closely. 4

Cancer‑Related Delirium

• In patients with cancer‑associated delirium, initiate quetiapine at 25 mg orally as needed; if scheduled dosing is required, give the dose every 12 hours.
• Reduce the dose in older adults and in those with hepatic impairment.
• Because quetiapine is sedating, monitor for orthostatic hypotension and dizziness, but note that it has a lower propensity to cause extrapyramidal symptoms compared with other atypical antipsychotics. 5

Monitoring for Orthostatic Hypotension During Initiation

• Transient orthostatic hypotension commonly occurs during the initial titration phase of quetiapine therapy; clinicians should assess blood pressure and symptoms after dose increases, especially in vulnerable populations. 4

Quetiapine Use in Geriatric Patients: Evidence‑Based Dosing and Safety

Dosing Recommendations for Cancer‑Related Delirium

In elderly patients with cancer‑associated delirium, low‑dose quetiapine is recommended.

• Start with 25 mg orally as needed, and schedule 25 mg every 12 hours (≈50 mg/day). Dose reductions should be applied for older adults to minimize adverse effects. 6

For tapering from higher doses, target ranges differ by indication (all derived from the same oncology study):

• Dementia‑related agitation: reduce to a maximum of 25–400 mg/day.
• Delirium: taper within one week after symptom resolution.
• Late‑life schizophrenia: taper to 100–300 mg/day.
• Depression: taper to 50–300 mg/day. (All dose‑adjustment guidance based on the 2018 oncology evidence.) 6

Safety Profile in Severe Agitation (Emergency Settings)

Among antipsychotics used for acute severe agitation in older adults, oral quetiapine demonstrated the most favorable safety outcomes.

• Emergency clinicians should initiate the lowest effective dose and avoid high‑dose regimens. (Guidance derived from a 2025 American Geriatrics Society study.) 7

Frequency of Adverse Events in Elderly Patients

In a 2025 cohort of older adults receiving antipsychotic or anxiolytic therapy, serious adverse events occurred in 16.8 % of patients, with incidence varying by specific drug and dose. 7

Common adverse events reported in geriatric patients on quetiapine include:

• Postural hypotension: observed in approximately 13–15 % of patients.
• Dizziness: reported in about 14–17 % of patients.
• Somnolence: noted in roughly 31–32 % of patients. (All rates derived from the same American Geriatrics Society analysis.) 7

Risks Associated with High Doses and Plasma Concentrations

Elevated quetiapine doses and plasma levels are linked to serious complications in older adults.

• Intubation risk and QTc prolongation increase with doses exceeding typical therapeutic ranges (e.g., >3 g total daily dose or peak concentrations >2 mg/L). (Evidence from the 2025 American Geriatrics Society report.) 7

All cited facts are drawn from peer‑reviewed studies (Annals of Oncology 2018; Journal of the American Geriatrics Society 2025) and reflect the strength of evidence reported in those sources.